Back to All

LAG-3: new biomarker under investigation in immuno-oncology

31 May, 2019

LAG-3, or lymphocyte activation gene 3, is a prominent new biomarker currently being researched in immuno-oncology. LAG-3 is an immune checkpoint receptor protein located on the cell surface of certain T cells involved in the immune response.1 LAG-3 expression is associated with T cell desensitization, which results in the progressive loss of the ability to trigger an immune response.In cancer, LAG-3–expressing cells cluster at tumor sites.3,4  

Preclinical studies have shown that the inhibition of LAG-3 improves T cell ability to coordinate immune response.5 Additionally, combining the inhibition of LAG-3 with other immune pathways (eg, anti-programmed cell death-1 [PD-1], anti-PD-1 ligand expression [PD-L1] checkpoint inhibitors) in order to promote anti-tumor activity is another therapeutic approach currently under investigation.

search of LAG-3 in the 2019 ASCO Abstracts database revealed multiple studies on this promising biomarker are underway. 

References 

  1. Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One. 2014 Nov 5;9(11):e109080.
  2. Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol. 2011; 344:269–278. 
  3. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004; 21(4):503-513.     
  4. Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4+ CD25high Foxp3+ regulatory T cells that are expanded at tumor sites. J Immunol. 2010; 184(11):6545-6551.     
  5. Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CDS+ T cell accumulation and effector function in murine self and tumor-tolerance systems. J Clin Invest. 2007;117(11):3383-3392.
  6. Lichtenegger FS, Rothe M, Schnorfeil FM, et al. Targeting LAG-3 and PD-1 to enhance t cell activation by antigen-presenting cells. Front Immunol. 2018 Feb 27;9:385.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.